ATE495195T1 - Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e - Google Patents

Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e

Info

Publication number
ATE495195T1
ATE495195T1 AT07795599T AT07795599T ATE495195T1 AT E495195 T1 ATE495195 T1 AT E495195T1 AT 07795599 T AT07795599 T AT 07795599T AT 07795599 T AT07795599 T AT 07795599T AT E495195 T1 ATE495195 T1 AT E495195T1
Authority
AT
Austria
Prior art keywords
hgf
growth factor
hepatocyte growth
binding protei
protei
Prior art date
Application number
AT07795599T
Other languages
English (en)
Inventor
William Winston
S Wright
May Han
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Arnold Horwitz
Original Assignee
Aveo Pharmaceuticals Inc
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Xoma Technology Ltd filed Critical Aveo Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE495195T1 publication Critical patent/ATE495195T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07795599T 2006-06-02 2007-06-01 Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e ATE495195T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
ATE495195T1 true ATE495195T1 (de) 2011-01-15

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07795599T ATE495195T1 (de) 2006-06-02 2007-06-01 Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e

Country Status (20)

Country Link
US (5) US7649083B2 (de)
EP (2) EP2361934A3 (de)
JP (3) JP4686634B2 (de)
KR (1) KR101196060B1 (de)
AR (1) AR061171A1 (de)
AT (1) ATE495195T1 (de)
AU (1) AU2007254942B2 (de)
BR (1) BRPI0712222B1 (de)
CA (1) CA2654025C (de)
CY (1) CY1111714T1 (de)
DE (1) DE602007011923D1 (de)
DK (1) DK2027156T3 (de)
IL (2) IL195037A (de)
MX (1) MX2008014829A (de)
NO (1) NO345476B1 (de)
NZ (1) NZ573818A (de)
PL (1) PL2027156T3 (de)
PT (1) PT2027156E (de)
SG (1) SG158112A1 (de)
WO (1) WO2007143090A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
ES2378097T3 (es) * 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
ATE495195T1 (de) * 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
EP3009148B1 (de) 2007-07-02 2018-08-22 Oncomed Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
CA2706732A1 (en) 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2009114748A1 (en) * 2008-03-14 2009-09-17 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
CA2725873C (en) 2008-05-29 2018-05-01 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
CN102131524B (zh) 2008-11-07 2014-05-14 星系生物科技责任有限公司 成纤维细胞生长因子受体2的单克隆抗体
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
EP2588107A1 (de) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Kombination aus einem cmet-hemmer und einem antikörper gegen hgf und/oder cmet
CA2808236A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
EP3252076B1 (de) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostische verwendung von antikörpern gegen das protein ror-1
EP3401329A1 (de) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Rspo-bindende stoffe und ihre verwendung
US20140234328A1 (en) 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
US20130078252A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
JP6335896B2 (ja) 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ３結合剤およびその使用法
EP2958592A1 (de) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Verfahren zur behandlung von krebs und zur verhinderung von arzneimittelresistenz
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2014153166A2 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Therapeutic use of antibodies to hgf
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
RU2652880C2 (ru) * 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Антитело против рецептора эпидермального фактора роста
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
MA40363A (fr) * 2014-08-15 2017-06-21 Oncomed Pharm Inc Agents de liaison de rspo1 et leurs utilisations
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
CN114729358A (zh) 2019-08-12 2022-07-08 因特尔纳技术有限公司 涉及miRNA-193a的新疗法
CA3167367A1 (en) 2020-02-28 2021-09-02 Sanaz YAHYANEJAD Mirna-193a for promoting immunogenic cell death
WO2022042673A1 (zh) * 2020-08-28 2022-03-03 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (de) 1991-12-13 2003-03-12 Xoma Corporation Verfahren und Materialien zur Herstellung von modifizierten Antikörper Variablen Domänen und deren therapeutischen Verwendung
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
EP2305027B1 (de) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgene Saügertiere, die menschlichen Ig-loci einschließlich mehrere VH und Vkappa Regionen enthalten, und davon erhaltene Antikörper
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
MXPA06000508A (es) 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
MX2007015056A (es) 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
ES2378097T3 (es) 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
JP2013090632A (ja) 2013-05-16
US7943344B2 (en) 2011-05-17
JP2011072318A (ja) 2011-04-14
DE602007011923D1 (de) 2011-02-24
CA2654025A1 (en) 2007-12-13
NO345476B1 (no) 2021-02-22
EP2361934A3 (de) 2011-11-02
NO20085421L (no) 2009-02-27
US8273355B2 (en) 2012-09-25
AU2007254942B2 (en) 2011-10-27
AR061171A1 (es) 2008-08-06
WO2007143090A3 (en) 2008-03-13
SG158112A1 (en) 2010-01-29
US20100173362A1 (en) 2010-07-08
AU2007254942A2 (en) 2009-05-28
US7649083B2 (en) 2010-01-19
EP2027156A2 (de) 2009-02-25
MX2008014829A (es) 2009-01-29
JP5735476B2 (ja) 2015-06-17
CY1111714T1 (el) 2015-10-07
EP2027156B1 (de) 2011-01-12
IL195037A (en) 2015-08-31
HK1129395A1 (en) 2009-11-27
WO2007143090A2 (en) 2007-12-13
JP2009539347A (ja) 2009-11-19
DK2027156T3 (da) 2011-04-26
BRPI0712222B1 (pt) 2021-10-13
AU2007254942A1 (en) 2007-12-13
PL2027156T3 (pl) 2011-06-30
US8580930B2 (en) 2013-11-12
EP2361934A2 (de) 2011-08-31
KR20090027226A (ko) 2009-03-16
US20130203963A1 (en) 2013-08-08
KR101196060B1 (ko) 2012-11-01
JP4686634B2 (ja) 2011-05-25
IL219654A0 (en) 2012-06-28
NZ573818A (en) 2011-09-30
IL195037A0 (en) 2011-08-01
AU2007254942A8 (en) 2009-02-05
CA2654025C (en) 2016-08-02
PT2027156E (pt) 2011-04-18
EP2027156B9 (de) 2011-03-30
US20080108565A1 (en) 2008-05-08
BRPI0712222A2 (pt) 2012-01-10
US20110229462A1 (en) 2011-09-22
US20140178935A1 (en) 2014-06-26
US9096664B2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
ATE495195T1 (de) Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
ATE533787T1 (de) Hepatozytenwachstumsfaktor (hgf)-bindende proteine
NO20201120A1 (no) Bindingsvirkninger
NO20082564L (no) Hepatosyttvekstfaktorintronfusjonsproteiner
DK2046826T3 (da) Exendin-fusionsproteiner
IL246531B (en) Modifying a chart
DK3118221T3 (da) Proteiner
NO20082030L (no) Styrt voltametri
EP2215246A4 (de) Proteingerüste
DK2203551T3 (da) Bifidobakterieart
BRPI0815075A2 (pt) Aglutinantes
EP2218175A4 (de) Schaltverstärker
DK2094292T3 (da) Salpeteroxid-blokeret tværbundet tetramerisk hæmoglobin
EP2005957A4 (de) Säuresekretionshemmer
DK2032551T3 (da) Antitumorale dihydropyran-2-on-forbindelser
EP2058942A4 (de) Digitaler verstärker
EP2229707A4 (de) Mikrowellenfilter
FI20075144L (fi) Intubaatioapuväline
ZA200809483B (en) Hepatocyte growth factor (HGF) binding proteins
FI20065201A0 (fi) Poikkisuuntainen venytyslaite
FI20065195L (fi) Parannettu yhteysratkaisu
FI20065625A0 (fi) Ilmanvaihdon päätelaite
DE112007000480A5 (de) Filtervorrichtung
ITCN20060002A1 (it) Imbiellaggio martino
FI20050547A0 (fi) Side

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2027156

Country of ref document: EP